Literature DB >> 20951449

Voice after radiotherapy of the larynx carcinoma.

Grażyna Niedzielska1, Antoni Niedzielski, Danuta Toman.   

Abstract

BACKGROUND: The study presents the evaluation of the phonatory function of the larynx after radiotherapy. The research covered the patients from the rural areas of Poland who revealed neoplastic changes in the glottis area.
MATERIAL AND METHODS: The test group consisted of 45 men aged 41-78 years with the carcinoma of the larynx with T1 and T2 progression types of cancer, according to the TNM classification. The analysis of laryngeal tone was performed with the digital analyzer Kay Elemetrics Model CSL 4300 and Multi Dimensional Voice Program (MDVP). A stroboscopic test in all the patients with T1 progression revealed the reduction of vibrations.
RESULTS: The acoustic analysis of the voice in the pre-treatment group as compared with the control group allowed for differentiation of the following parameters of a definitely pathologic character: Jita, Jitter, RAP, PPQ, vFo, Shimmer, APQ, vAm, NHR, VTI, SPI, and DUV.
CONCLUSIONS: In the acoustic analysis of voice in the post-radiotherapy group, the following parameters reached values close to the norm: JITA, JITT, RAP, PPQ, vF0, vAM, DUV, and Schimmer dB.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20951449     DOI: 10.1016/j.radonc.2010.09.019

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

Review 1.  Dysphagia, Speech, Voice, and Trismus following Radiotherapy and/or Chemotherapy in Patients with Head and Neck Carcinoma: Review of the Literature.

Authors:  B J Heijnen; R Speyer; B Kertscher; R Cordier; K W J Koetsenruijter; K Swan; H Bogaardt
Journal:  Biomed Res Int       Date:  2016-09-19       Impact factor: 3.411

2.  Quality of life in Chinese patients with laryngeal cancer after radiotherapy.

Authors:  Ji-Wei Mu; Mei-Jia Zhang; Bi-Qi Luan; Jian Wu; Ping Sun
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.